Health Care · Surgical & Medical Instruments & Apparatus

SIBN SI-BONE, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1459839114 filings
Russell 2000

SIBN at a glance

SI-BONE, Inc. (SIBN, SEC CIK 1459839) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), SI-BONE, Inc. (SIBN) reported revenue of $200.9 million (up 20.2% from FY2024) and a net loss of $18.9 million. Diluted EPS was -$0.44.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding SI-BONE, Inc. (SIBN) shares worth $229.0 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by FRANCIS LAURA on November 17, 2026 of 1,901 shares at $23.18 per share.
  • In the last 90 days, SIBN insiders reported 0 open-market purchases ($0) and 31 open-market sales ($8.0M) on Form 4, a net sale of $8.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$200.9M
+20.2% vs prior year
Insiders · 90 days
0 buys · 31 sells
Net −$8.0M
13F holders
25 funds
$229.0M · −1 vs prior quarter
Latest 8-K
Nov 2, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $55.7M, up 14.5% YoY from $48.7M, driven by 19.5% procedure-volume growth
  • Gross margin 79.3% vs 79.8% YoY, reflecting site-of-care and procedure-mix changes
  • U.S. revenue $52.8M, up 13.9%; international revenue $2.9M, up 27.0%
  • Operating cash flow $4.4M vs $(2.4)M YoY; investing outflow $13.1M, including $9.0M equipment purchases
  • Cash and marketable securities $146.3M vs $147.8M at December 31, 2025; funding expected for next 12 months, with downturn and capital-market risks

Risk Factors

  • New operational risk: tube packaging failure affected approximately 3,900 iFuse TORQ implants, including 98 voluntarily recalled units
  • Regulatory risk: FDA Class II recall reporting followed potentially compromised sterility in iFuse TORQ implants
  • Supply-chain risk: titanium availability and costs exposed to Russia-Ukraine disruptions and potential tariffs
  • Product-liability risk: nonsterile packaging could increase infection risk and require revision surgery
  • Manufacturing risk: limited-source components and contract sterilization constraints could disrupt product availability

AI summary of the SIBN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 2, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces SI-BONE results for the quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, profitability, guidance and operating metrics influencing valuation

Item EX-99.1: Item EX-99.1

  • Q3 revenue $55.7M, up 14.5%, with U.S. procedure volume growth of approximately 19.5% offset by lower average selling price
  • Net loss narrowed 20.7% to $3.6M, while adjusted EBITDA rose 32.4% to $3.0M and operating cash flow reached $5.9M
Filed Sep 11, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Headquarters lease extended one month through October 31, 2026
  • $43,696 October base rent for 21,848 square feet in Santa Clara

Item 8.01: Other Events

  • Voluntary recall of 98 iFuse TORQ implants over packaging sterility-barrier failures and potential infection risk
  • Two recalled implants were implanted; no infections or adverse events reported as of filing date

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 signals a new direct financial obligation, with terms contained in Item 1.01
  • Investors should review the related agreement for amount, interest rate, maturity and borrowing purpose
Filed Aug 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • SI-BONE announced financial results for the quarter ended June 30, 2026
  • Full operating metrics, financial results and management commentary are in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q2 revenue $56.0M, up 15.2%, with U.S. procedure volume growth of 14.9%
  • Adjusted EBITDA $2.8M versus $1.0M, while net loss narrowed to $4.1M from $6.2M

AI summaries of SIBN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SIBN

Don't miss the next SIBN filing

  • Alerts as it files. A push when SIBN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SIBN, by share count.
  • Ask anything. An AI agent that reads every SIBN filing and answers with sources.

SIBN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
FRANCIS LAURASellNov 17, 2026$23.18
Maheshwari AnshulSellNov 17, 2026$23.19
FRANCIS LAURASellNov 16, 2026$23.33
Maheshwari AnshulSellNov 16, 2026$23.34
FRANCIS LAURASellNov 16, 2026$23.33
FRANCIS LAURASellNov 16, 2026$23.32
PISETSKY MICHAEL A.SellNov 16, 2026$23.31
PISETSKY MICHAEL A.SellNov 16, 2026$23.32

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$167.2M$200.9M
Gross Profit-$132.1M$159.9M
Operating Income--$35.2M-$22.3M
Net Income--$30.9M-$18.9M
Gross Margin-79.0%79.6%
Op. Margin--21.1%-11.1%
Net Margin--18.5%-9.4%
Balance Sheet
Total Assets$230.4M$230.4M$238.6M
Equity-$167.0M$177.5M
ROE--18.5%-10.6%
Per Share
EPS-$-0.75$-0.44
Cash Flow
Operating CF--$12.4M-$675K
CapEx$7.8M$10.5M$8.4M

Source: XBRL data in SI-BONE, Inc. (SIBN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SIBN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SIBN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$229.0M
Q2 202626$178.1M
Q1 202628$143.5M
Q4 202525$218.5M
Q3 202525$164.5M
Q2 202525$207.4M
Q1 202522$92.7M
Q4 202417$70.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SIBN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 9, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
4Nov 4, 2026--
10-QNov 3, 2026Analysis
8-KNov 2, 2026Analysis-
4Nov 2, 2026--
4Nov 2, 2026--
4Oct 14, 2026--
4Oct 6, 2026--
4Oct 6, 2026--
4Oct 5, 2026--
8-KSep 11, 2026Analysis-
4Sep 3, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 21, 2026--
4Aug 21, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--

Related Health Care companies

All Health Care →

SIBN SEC filings: frequently asked questions

Are SIBN insiders buying or selling?

In the last 90 days, SI-BONE, Inc. (SIBN) officers, directors and 10% owners reported no open-market purchases and 31 open-market sales worth $8.0 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold SIBN stock?

As of September 30, 2026, the largest SI-BONE, Inc. (SIBN) holders among the 13F filers tracked by SignalX were BlackRock ($70.0 million), Vanguard Capital Management LLC ($35.5 million), State Street Corp ($23.4 million), Millennium Management ($17.4 million), Dimensional Fund Advisors ($13.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SIBN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), SI-BONE, Inc. (SIBN) reported revenue of $200.9 million (up 20.2% from FY2024) and a net loss of $18.9 million. Diluted EPS was -$0.44. The figures come from the XBRL data in the 10-K.

What did SIBN report in its latest 8-K?

SI-BONE, Inc. (SIBN) filed an 8-K on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces SI-BONE results for the quarter ended September 30, 2026.

What are the latest SIBN SEC filings?

SI-BONE, Inc. (SIBN) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 18, 2026.

What is SIBN's SEC CIK number?

SI-BONE, Inc. (SIBN)'s SEC Central Index Key (CIK) is 1459839. EDGAR lists every SIBN filing under that number.

Ask anything about SIBN

The research agent reads SIBN's filings, financials, insider trades and 13F holders, then answers with sources.